keyword
https://read.qxmd.com/read/38612415/cannabinoids-and-sleep-exploring-biological-mechanisms-and-therapeutic-potentials
#1
JOURNAL ARTICLE
Martina D'Angelo, Luca Steardo
The endogenous cannabinoid system (ECS) plays a critical role in the regulation of various physiological functions, including sleep, mood, and neuroinflammation. Phytocannabinoids such as Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinomimimetics, and some N-acylethanolamides, particularly palmitoyethanolamide, have emerged as potential therapeutic agents for the management of sleep disorders. THC, the psychoactive component of cannabis, may initially promote sleep, but, in the long term, alters sleep architecture, while CBD shows promise in improving sleep quality without psychoactive effects...
March 22, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38611895/inflammatory-targeted-lipid-carrier-as-a-new-nanomaterial-to-formulate-an-inhaled-drug-delivery-system
#2
JOURNAL ARTICLE
Eleonora Maretti, Federica Gioia, Cecilia Rustichelli, Susanna Molinari, Eliana Leo
There is a pressing need for efficacious therapies in the field of respiratory diseases and infections. Lipid nanocarriers, administered through aerosols, represent a promising tool for maximizing therapeutic concentration in targeted cells and minimizing systemic exposure. However, this approach requires the application of efficient and safe nanomaterials. Palmitoylethanolamide (PEA), an endocannabinoid-like endogenous lipid, plays a crucial role in providing protective mechanisms during inflammation, making it an interesting material for preparing inhalable lipid nanoparticles (LNPs)...
April 3, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38611871/oleoylethanolamide-and-palmitoylethanolamide-enhance-ifn%C3%AE-induced-apoptosis-in-human-neuroblastoma-sh-sy5y-cells
#3
JOURNAL ARTICLE
Chiara Camoglio, Jihane Balla, Paola Fadda, Simona Dedoni
Oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are endogenous lipids that act as agonists of the peroxisome proliferator-activated receptor α (PPARα). Recently, an interest in the role of these lipids in malignant tumors has emerged. Nevertheless, the effects of OEA and PEA on human neuroblastoma cells are still not documented. Type I interferons (IFNs) are immunomodulatory cytokines endowed with antiviral and anti-proliferative actions and are used in the treatment of various pathologies such as different cancer forms (i...
April 2, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38533175/the-comparative-efficacy-of-palmitoylethanolamide-pea-with-the-combination-of-pregabalin-and-nortriptyline-on-post-extraction-trigeminal-neuropathy-by-using-magnetic-resonance-mr-neurography-a-randomized-clinical-trial
#4
JOURNAL ARTICLE
Amlendu Shekhar, Adit Srivastava, Nimisha Verma, Ashish Verma, T P Chaturvedi
Aim The aim of this randomized clinical trial is to compare the efficacy of palmitoylethanolamide (PEA) with the combination of pregabalin and nortriptyline in treating post-extraction trigeminal neuropathy using magnetic resonance neurography (MRN). Methods The present prospective, randomized controlled trial was conducted on 60 patients (20 in each group). In group I (positive control group), a combination of 75 mg of pregabalin and 10 mg of nortriptyline was administered once daily for the duration of 12 weeks...
February 2024: Curēus
https://read.qxmd.com/read/38533051/therapeutic-potential-of-clinically-proven-natural-products-in-the-management-of-dementia
#5
REVIEW
Farzana Ansari, Md Sohel, Md Mahfujul Haque Haidary, Md Saqline Mostaq, Shamima Akter, Asrafun Nahar, Fatematuz Zohora Labony, Arman Ahmed, Mohammed Shamim Hasan, Mohammad Hasem Babu, Mohammad Nurul Amin
Dementia is a common neurodegenerative disorder connected to damage to nerve cells in the brain. Although some conventional drugs are available for dementia treatments and are still sanctified for dementia patients, their short- and long-term side effects and other limitations make treating patients more challenging. The authors aimed to explain novel options for treating dementia with natural products and unravel some clinically proven natural products. This article systematically reviewed recent studies that have investigated the role of natural products and their bioactive compounds for dementia...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38513506/corrigendum-to-adelmidrol-a-palmitoylethanolamide-analogue-as-a-new-pharmacological-treatment-for-the-management-of-acute-and-chronic-inflammation-biochem-pharmacol-119-2016-27-41
#6
Daniela Impellizzeri, Rosanna Di Paola, Marika Cordaro, Enrico Gugliandolo, Giovanna Casili, Valeria Maria Morittu, Domenico Britti, Emanuela Esposito, Salvatore Cuzzocrea
No abstract text is available yet for this article.
March 20, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38492007/persistent-covid-19-parosmia-and-olfactory-loss-post-olfactory-training-randomized-clinical-trial-comparing-central-and-peripheral-acting-therapeutics
#7
JOURNAL ARTICLE
Elena Cantone, Luca D'Ascanio, Pietro De Luca, Dalila Roccamatisi, Ignazio La La Mantia, Michael J Brenner, Arianna Di Stadio
PURPOSE: Although COVID-19 anosmia is often transient, patients with persistent olfactory dysfunction (pOD) can experience refractory parosmia and diminished smell. This study evaluated four putative therapies for parosmia in patients with chronic COVID-19 olfactory impairment. METHODS: After screening nasal endoscopy, 85 patients (49 female, 58%) with pOD and treatment-refractory parosmia were randomized to: (1) ultramicronized palmitoylethanolamide and luteolin + olfactory training (OT) (umPEALUT group, n = 17), (2) alpha-lipoic acid + OT (ALA group, n = 21), (3) umPEALUT + ALA + OT (combination group, n = 28), or 4) olfactory training (OT) alone (control group, n = 23)...
March 16, 2024: European Archives of Oto-rhino-laryngology
https://read.qxmd.com/read/38479039/palmitoylethanolamide-and-polydatin-in-pediatric-irritable-bowel-syndrome-a-multicentric-randomized-controlled-trial
#8
JOURNAL ARTICLE
Giovanni Di Nardo, Luca Bernardo, Cesare Cremon, Giovanni Barbara, Enrico Felici, Melania Evangelisti, Alessandro Ferretti, Silvia Furio, Marisa Piccirillo, Flaminia Coluzzi, Pasquale Parisi, Angela Mauro, Clelia Di Mari, Francesco D'Angelo, Maurizio Mennini
OBJECTIVE: This study aimed to evaluate the efficacy and safety of co-micronized palmitoylethanolamide (PEA)/polydatin (PD) in the treatment of abdominal pain symptoms in pediatric patients with irritable bowel syndrome (IBS). METHODS: This was a multicenter trial conducted at three Italian pediatric gastroenterology centers, employing a double-blind, placebo-controlled, parallel-arm design. Participants were ages 10 to 17 y and met Rome IV criteria for pediatric IBS...
February 15, 2024: Nutrition
https://read.qxmd.com/read/38472653/retraction-note-to-the-association-of-palmitoylethanolamide-with-luteolin-decreases-autophagy-in-spinal-cord-injury
#9
Rosalba Siracusa, Irene Paterniti, Giuseppe Bruschetta, Marika Cordaro, Daniela Impellizzeri, Rosalia Crupi, Salvatore Cuzzocrea, Emanuela Esposito
No abstract text is available yet for this article.
March 12, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38431786/efficacy-of-mast-cell-directed-therapies-in-irritable-bowel-syndrome-a-systematic-review
#10
REVIEW
D Coppens, M Kips, T Stiévenard, C Mertens, H De Schepper
BACKGROUND AND STUDY AIM: Lately, mast cells (MCs) are increasingly implicated in the pathophysiology of irritable bowel syndrome (IBS). The aim of this systematic review was to assess the efficacy of mast cell directed therapies in reducing the main symptoms of IBS: abdominal pain and changes in stool frequency or consistency. PATIENTS AND METHODS: Pubmed, Web of Science and Scopus were searched until December 19, 2022. Trials evaluating the efficacy of mast cell directed therapies, compared to placebo or any form of control group, were included...
2024: Acta Gastro-enterologica Belgica
https://read.qxmd.com/read/38408443/efficacy-of-topical-palmitoylethanolamide-levagen-for-the-management-of-eczema-symptoms-a-double-blind-comparator-controlled-randomized-clinical-trial
#11
JOURNAL ARTICLE
Amanda Rao, Amel A Moussa, Jane Erickson, David Briskey
INTRODUCTION: Eczema is a debilitating skin disorder clinically characterised by the development of itchy, dry, rough, and scaling skin caused by a series of rudimentary clinical phenotypes. METHODS: This double-blind, randomised, comparator-controlled trial evaluated the effectiveness of topical application of a novel palmitoylethanolamide formulation (Levagen+) compared with a standard moisturiser (comparator) to reduce eczema severity and improve patient outcomes...
February 26, 2024: Skin Pharmacology and Physiology
https://read.qxmd.com/read/38399360/effectiveness-of-palmitoylethanolamide-levagen-compared-to-a-placebo-for-reducing-pain-duration-and-medication-use-during-migraines-in-otherwise-healthy-participants-a-double-blind-randomised-controlled-study
#12
JOURNAL ARTICLE
David Briskey, Rachael Skinner, Chelsie Smith, Amanda Rao
Migraines are a common neurological disorder that generally affects young to middle-aged adults and females more than males. Various treatment options are available; however, these can cause undesirable side effects. Therefore, alternative treatments with minimal side effects are still being investigated. Palmitoylethanolamide (PEA) is a signalling lipid known to have anti-inflammatory and analgesic properties. Previous prophylactic research has reported PEA supplementation to decrease pain associated with migraines...
January 23, 2024: Pharmaceuticals
https://read.qxmd.com/read/38398813/formulated-palmitoylethanolamide-supplementation-improves-parameters-of-cognitive-function-and-bdnf-levels-in-young-healthy-adults-a-randomised-cross-over-trial
#13
JOURNAL ARTICLE
Nadia Kim, Brenda Parolin, Derek Renshaw, Sanjoy K Deb, Mohammed Gulrez Zariwala
BACKGROUND: Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator which is naturally produced in the body and found in certain foods. The aim of this study was to assess the effect of a bioavailable formulated form of PEA (Levagen+® ) on serum BDNF levels and parameters of cognitive function in healthy adults. METHODS: A randomised double-blinded placebo-controlled cross-over trial was implemented to measure the effects of a 6-week 700 mg/day course of formulated PEA supplementation versus a placebo...
February 8, 2024: Nutrients
https://read.qxmd.com/read/38392596/prevention-of-protease-induced-degradation-of-desmoplakin-via-small-molecule-binding
#14
JOURNAL ARTICLE
Isabel M Romov, Roujon A Nowzari, Clay P Page, Madeleine R Benes, Maegen A Borzok, Nathan T Wright
Desmoplakin (DSP) is a large (~260 kDa) protein found in the desmosome, the subcellular structure that links the intermediate filament network of one cell to its neighbor. A mutation "hot-spot" within the NH2 -terminal of the DSP protein (residues 299-515) is associated with arrhythmogenic cardiomyopathy. In a subset of DSP variants, disease is linked to calpain hypersensitivity. Previous studies show that calpain hypersensitivity can be corrected in vitro through the addition of a bulky residue neighboring the cleavage site, suggesting that physically blocking calpain accessibility is a viable strategy to restore DSP levels...
January 31, 2024: Journal of Personalized Medicine
https://read.qxmd.com/read/38382784/lysosome-targeting-fluorescent-probe-for-naaa-imaging-and-its-applications-in-the-drug-development-for-anti-inflammatory
#15
JOURNAL ARTICLE
Limin Zhou, Manman Tian, Baojing Zhang, Xudong Cao, Xiaokui Huo, Fangyu Yang, Peng Cao, Lei Feng, Xiaochi Ma, Xiangge Tian
N-acylethanolamine acid amidase (NAAA) is a nucleophilic lysosomal cysteine hydrolase, which primarily mediates the hydrolytic inactivation of endogenous palmitoylethanolamide (PEA), which further influences the inflammatory process by regulating peroxisome proliferator-activated receptor-α (PPARα). Herein, a novel lysosome (Lyso)-targeting fluorescent probe (i.e., PMBD) was designed and synthesized for detecting endogenous NAAA selectively and sensitively, allowing real-time visual monitoring of endogenous NAAA in living cells...
February 19, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38381905/micronized-ultramicronized-palmitoylethanolamide-improves-depression-and-fatigue-in-coronavirus-disease-2019-covid-19-survivors
#16
JOURNAL ARTICLE
Aurora Merolla, Rebecca De Lorenzo, Giacomo Paolazzi, Sara Critelli, Mariagrazia Palladini, Sarah Damanti, Giordano Vitali, Valentina Canti, Marta Cilla, Sabina Martinenghi, Elisabetta Falbo, Marica Ferrante, Jacopo Castellani, Giacomo Pacioni, Cristiano Magnaghi, Anna Fumagalli, Mario G Mazza, Francesco Benedetti, Patrizia Rovere-Querini
Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and presenting neuropsychiatric manifestations (n = 98) were offered treatment with m/umPEA 600 mg twice daily for 3 months...
February 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38368184/corrigendum-to-palmitoylethanolamide-and-polydatin-combination-reduces-inflammation-and-oxidative-stress-in-vascular-injury-pharmacol-res-123-2017-83-92
#17
Enrico Gugliandolo, Roberta Fusco, Flavia Biundo, Ramona D'Amico, Filippo Benedetto, Rosanna Di Paola, Salvatore Cuzzocrea
No abstract text is available yet for this article.
February 16, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38296973/endocannabinoids-endocannabinoid-like-compounds-and-cortisone-in-head-hair-of-health-care-workers-as-markers-of-stress-and-resilience-during-the-early-covid-19-pandemic
#18
JOURNAL ARTICLE
Ingeborg Biener, Tonina T Mueller, Jin Lin, Han Bao, Julius Steffen, Marion Hoerl, Katharina Biere, Sandra Matzel, Tobias Woehrle, Simon König, Annekathrin M Keiler, Detlef Thieme, Oliver Keppler, Matthias Klein, Tobias Weinberger, Andreas Osterman, Kristina Adorjan, Alexander Choukér
The pandemic caused by SARS-CoV-2 impacted health systems globally, creating increased workload and mental stress upon health care workers (HCW). During the first pandemic wave (March to May 2020) in southern Germany, we investigated the impact of stress and the resilience to stress in HCW by measuring changes in hair concentrations of endocannabinoids, endocannabinoid-like compounds and cortisone. HCW (n = 178) recruited from multiple occupation and worksites in the LMU-University-Hospital in Munich were interviewed at four interval visits to evaluate mental stress associated with the COVID-19 pandemic...
January 31, 2024: Translational Psychiatry
https://read.qxmd.com/read/38296815/emerging-drugs-for-the-treatment-of-irritability-associated-with-autism-spectrum-disorder
#19
REVIEW
Ahmad Shamabadi, Hanie Karimi, Razman Arabzadeh Bahri, Mohsen Motavaselian, Shahin Akhondzadeh
INTRODUCTION: Autism spectrum disorder (ASD) is an early-onset disorder with a prevalence of 1% among children and reported disability-adjusted life years of 4.31 million. Irritability is a challenging behavior associated with ASD, for which medication development has lagged. More specifically, pharmacotherapy effectiveness may be limited against high adverse effects (considering side effect profiles and patient medication sensitivity); thus, the possible benefits of pharmacological interventions must be balanced against potential adverse events in each patient...
January 31, 2024: Expert Opinion on Emerging Drugs
https://read.qxmd.com/read/38273283/dysfunction-in-endocannabinoids-palmitoylethanolamide-and-degradation-of-tryptophan-into-kynurenine-in-individuals-with-depressive-symptoms
#20
JOURNAL ARTICLE
Stefano Comai, Nicolas Nunez, Tobias Atkin, Maykel F Ghabrash, Rita Zakarian, Allan Fielding, Marie Saint-Laurent, Nancy Low, Garrett Sauber, Eugenio Ragazzi, Cecilia J Hillard, Gabriella Gobbi
BACKGROUND: The endocannabinoid (eCB) system and the serotonin (5-HT) are both implicated in the severity of the depression. 5-HT is synthesized from the amino acid tryptophan (Trp), which is also a precursor for kynurenine (Kyn) whose production is increased at the expense of 5-HT in depressed patients. No clinical studies have investigated the crosstalk between the eCB system and the Trp/5-HT/Kyn pathways. Here, we hypothesized that the eCB system is associated with an enhanced Kyn production in relation to the severity of depressive symptoms...
January 25, 2024: BMC Medicine
keyword
keyword
60280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.